Register | Forgot Your Password? | Close

NEW YORK (AP) - Pfizer says that a long-lasting version of its anti-seizure drug Lyrica failed to significantly decrease epilepsy symptoms when compared with placebo.

The company said Friday that a study of two doses of once-a-day pregabalin CR showed the pills were well tolerated, but did not meet the study's goal of decreasing seizure frequency. The company tracked patients' seizures for 28 days while taking the drug and compared that rate to an 8-week baseline period.

Pfizer said it will continue with two other studies evaluating the drug for fibromyalgia and post-herpetic neuralgia.

Lyrica is Pfizer's top-selling drug with sales of $1.04 billion in the most recent quarter. The regular formulation of the drug is approved to prevent seizures and pain associated with diabetes, shingles and fibromyalgia.

Pfizer Inc. shares rose a penny to $23.67 in midday trading.


(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
share this story:
Attention KTAR.com Comment Users: We have recently changed our comments boards.
We would like you to be part of the conversation and The Voice of Arizona by logging in with your Facebook, Twitter, Google+ or Disqus account. Existing KTAR (Arizona Sports) account members will need to create a Disqus account or use one of the aforementioned social media logins. Thank you.
comments powered by Disqus